BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2026)

BioNexus Gene Lab's Operating Expenses history runs 9 years deep, the most recent figure standing at $597386.0 for Q1 2026.

• In Q1 2026, Operating Expenses fell 43.29% year-over-year to $597386.0; the TTM figure through Mar 2026 stood at $4.0 million (down 24.64% YoY), while the FY2025 annual figure was $4.5 million, down 9.18% from the prior year.
• Operating Expenses came in at $597386.0 for Q1 2026 at BioNexus Gene Lab, down from $1.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.2 million in Q3 2023 to a low of -$4.0 million in Q4 2023.
• A 5-year average of $1.0 million and a median of $1.1 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 1557.79% in 2022 and tumbled 506.52% in 2023, its largest moves.
• BioNexus Gene Lab's Operating Expenses stood at $975716.0 in 2022, then sank by 506.52% to -$4.0 million in 2023, then soared by 135.31% to $1.4 million in 2024, then decreased by 24.86% to $1.1 million in 2025, then sank by 43.23% to $597386.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $597386.0, $1.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison